Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases

Table 2 Relative luminescence units (RLU) of cytosolic adenylate kinase released from the hepatoma cell line HepG2 for HCC patients and the colorectal carcinoma cell line CaCo for patients with colorectal carcinoma metastatic to the liver

Tumor entity	CP	Etiology of	AK release before	AK release 4 wk	AK release 8 wk
		cirrhosis	RFA	after RFA	after RFA
HCC 1	A	alcohol	4.8	398.46	535.87
HCC 2	A	Hep C	3.26	421.66	645.9
HCC 3	B	Hep C	4.88	578.63	845.99
HCC 4	A	alcohol	3.95	865.66	1025.21
HCC 5	B	alcohol	5	465.7	732.13
HCC 6	A	alcohol	4.66	751.33	924.66
Mean			4.42	580.24b	784.96b
(SD)			0.68	190.81	181.73
Tumor entity	Primary		AK releasebefore	AK release4 wk	AK release8 wk
			RFA	after RFA	after RFA
CRC metastasis 1	Sigma		2.13	568.32	816.55
CRC metastasis 2	Colon		3	947.47	1298.25
CRC metastasis 3	Colon		2.79	627.55	945.33
CRC metastasis 4	Sigma		2.56	699.45	845.54
CRC metastasis 5	Rectum		2.98	598.65	932.17
CRC metastasis 6	Colon		2.27	621.46	889.66
Mean			2.62	677.15b	954.58b
(SD)			0.37	139.38	175.42

Cells were co-incubated with PBMC isolated from each patient taken before, 4 and 8 wk after RFA. CP: Child Pugh-Score of patients with liver cirrhosis; LC: liver cirrhosis; HCC: hepatocellular carcinoma; CRC metastasis: patients with colorectal cancer metastastatic to the liver; Primary: location of the primary tumor; m.d.: missing data;

^bP < 0.0001 vs bioluminescence before RFA.